A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma
David A. Reardon, Annick Desjardins, Olivier Rixe, Timothy F. Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie Turich Taylor, Andrew B. Lassman
Topics & Concepts
MedicinePharmacokineticsPharmacodynamicsAdverse effectInternal medicineDosingGastroenterologyToxicityGliomaIndoleamine 2,3-dioxygenasePharmacologyUrologyChemistryTryptophanAmino acidCancer researchBiochemistryTryptophan and brain disordersCancer-related cognitive impairment studiesSchizophrenia research and treatment